Supply Chain Council of European Union | Scceu.org
Supply Chain Risk

BlackRock Enhanced Government Fund Inc (EGF) to Issue Monthly Dividend of $0.04 on January 9th

BlackRock Enhanced Government Fund Inc (NYSE:EGF) announced a monthly dividend on Thursday, December 19th, Zacks reports. Investors of record on Tuesday, December 31st will be given a dividend of 0.041 per share on Thursday, January 9th. This represents a $0.49 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Monday, December 30th.

BlackRock Enhanced Government Fund has decreased its dividend by an average of 2.6% per year over the last three years.

EGF traded up $0.12 during trading on Friday, reaching $13.14. 2,933 shares of the stock traded hands, compared to its average volume of 8,997. BlackRock Enhanced Government Fund has a fifty-two week low of $12.77 and a fifty-two week high of $13.45. The stock’s 50-day simple moving average is $13.04 and its two-hundred day simple moving average is $13.02.

About BlackRock Enhanced Government Fund

BlackRock Enhanced Government Fund, Inc is a closed-ended fixed income mutual fund launched by BlackRock, Inc It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It primarily invests in a portfolio of United States government and government agency securities, including the U.S.

Further Reading: What is a stock buyback?

Dividend History for BlackRock Enhanced Government Fund (NYSE:EGF)



Receive News & Ratings for BlackRock Enhanced Government Fund Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BlackRock Enhanced Government Fund and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Taal expected to add more ‘urgency’ to legislation creating disaster resiliency dep’t

scceu

Kentucky mental health professionals dealing with case overload after multiple disasters – 89.3 WFPL News Louisville

scceu

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

scceu